Details of the Drug Combination

General Information of Drug Combination (ID: DCJVJL6)

• Drug Combination Name: CC-115 + Marizomib
• Indication: Diffuse intrinsic pontine glioma; Status: Investigative [1]
• Component Drugs:
  CC-115 (DMYEB5F): Small molecular drug
  Marizomib (DME9QGW): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: DIPG25
  Zero Interaction Potency (ZIP) Score: 4.02
  Bliss Independence Score: 3.14
  Loewe Additivity Score: 5.19
  LHighest Single Agent (HSA) Score: 7.57

Molecular Interaction Atlas of This Drug Combination

Indication(s) of CC-115

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 1	[2]
Non-hodgkin lymphoma	2B33.5	Phase 1	[2]

Indication(s) of Marizomib

Disease Entry	ICD 11	Status	REF
Glioblastoma of brain	2A00.00	Phase 3	[3]
Malignant glioma	2A00.0	Phase 1	[4]
Multiple myeloma	2A83	Phase 1	[4]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]

Marizomib Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Proteasome (PS)	TTU7ZMG	NOUNIPROTAC	Inhibitor	[6]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] ClinicalTrials.gov (NCT01353625) Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT03345095) A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma (MIRAGE). U.S. National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of Triphase Accelerator .
• [6] Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar;11(3):254-84.